Pharmafile Logo

Striving to become more patient-centric?

August 25, 2020 |  

Explore more with OPEN Health

Patients are increasingly involved in their healthcare decisions. They have become empowered and informed data-driven advocates for their own health. We are currently at a tipping point in the industry as regulatory bodies and patient advocacy groups have come together to reinforce the importance of the role of patients in the drug development process.

Why now?

  • Patient engagement tools have evolved considerably
  • There is an increased role of patients in regulatory and health technology decision making
  • Healthcare players who are unable or unwilling to deepen collaborations in the industry may find it difficult, if not impossible, to participate in a future patient-driven healthcare system

But how does a patient-centric approach evolve from a one-off engagement tactic to a fully integrated, company-wide practice?

Join us and take an interactive tour through today’s modern approach to patient-centricity. We will show how patient-centricity can be integrated into all phases of development and commercialization and show examples of how to achieve patient buy-in and ensure the patient voice is represented in your study outcomes.

Start Your Journey

In this interactive journey, you will:

  • Learn about the value of a patient-centric approach
  • Explore areas to focus on at different phases of the product life cycle
  • See real-life case studies of how a patient-centric approach can be used in therapeutic areas such as oncology, rare disease and advanced therapies
  • Find out how to take your first step to a patient-centric approach
  • Meet our team of experts and what drives them

Pink divider

Pharmerit – an OPEN Health Company has been at the forefront of the evolution of patient-centricity. We have seen the positive impact of engaging patients throughout the product lifecycle. We believe it is important to include patient-centricity in every project we undertake, combining expertise with outcomes to see the impact of co-creation.

This content was provided by OPEN Health

Company Details

 Latest Content from  OPEN Health 

Delivering change through better rare disease communications

OPEN Health’s Richard Jones, Gemma Allen and Charlotte Richards discuss how pharma can utilise tools, channels and stakeholders to deliver change and enable better outcomes.

CSR ‘Christmas Spirit’ 2019

OPEN Health champions CSR over Christmas by giving back to the community and increasing our  activities and efforts

Spotlight interview: 15 minutes on Independent Medical Education

Celeste Kolanko, Managing Director of Liberum, OPEN Health takes 15 minutes to answer some key questions on independent medical education.

OPEN Health supports Genetic Alliance UK’s Rare Film Festival!

OPEN Health joined a number of rare disease patients, patient groups and industry representatives at the Regent Street cinema in London to see the winners announced at the Rare Film...

Empowering and equipping medical affairs teams to embrace an ever-expanding remit

Written by Jess Ingram and Francisca Costa, OPEN Health

The role of medical affairs in positive and appropriate engagement with patient advocacy groups

Written by Gavin Jones, Dr Alexandra Safronova & Professor Peter Rutherford, OPEN Health